Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,532 across all filing types
Latest filing 2026-06-17 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Transaction in Own Shares Classification · 95% confidence The document is titled as a 'Voluntary Announcement' about an 'On-Market Purchase of Shares Pursuant to the 2026 Share Award Scheme'. It details the number of shares purchased on-market by the trustee for the share award scheme, including specifics such as total shares, average price, and percentage of shares held. It is an announcement about the company buying its own shares under a share award scheme, rather than a financial report or an extensive analysis. The text is only 3005 characters long and focused solely on share repurchase activity under a specific share award scheme. Based on the definitions, the appropriate classification is 'Transaction in Own Shares' (POS) which covers report of the company buying back shares or selling its own shares for repurchase or issuance plans.
2026-06-17 English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited about the acceptance of a marketing authorization application for a pharmaceutical product by the National Medical Products Administration (NMPA) of China. It provides detailed information about the product's clinical advantages, study results, and regulatory status but does not include financial statements, performance metrics, or shareholder votes. The tone and content focus on regulatory and product development updates rather than financial or governance reporting. The document is relatively short (4618 characters) and serves as an announcement rather than a full report. Therefore, this fits the category of a Regulatory Filing (RNS), which includes miscellaneous regulatory announcements not fitting other specific categories.
2026-06-16 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a Hong Kong listed company about on-market purchases of shares under a newly adopted share award scheme. It details the number of shares purchased, the average price, and shares held in trust. The document is a voluntary announcement related to the company's share award scheme and share purchase activities. It does not contain financial statements or comprehensive financial results. The content fits the category of Transaction in Own Shares (POS), which covers reports of share repurchase or issuance activities by the company.
2026-06-16 English
VOLUNTARY ANNOUNCEMENT - PACLITAXEL FOR INJECTION (ALBUMIN-BOUND) (II) RECEIVES MARKETING APPROVAL
Regulatory Filings Classification · 95% confidence The document is an announcement titled 'VOLUNTARY ANNOUNCEMENT' about a marketing approval received for a pharmaceutical product by the company CSPC Pharmaceutical Group Limited. It includes details about the product, clinical trial results, and implications for the company’s competitiveness. There is no financial data, no report attached or referenced as released, and the announcement is short (3502 characters). It does not represent an annual or interim financial report, earnings release, or any management or governance report. It is a standalone company announcement regarding a product approval, which best fits under the Regulatory Filings category as a general regulatory announcement that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-06-15 English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST
Regulatory Filings Classification · 76% confidence The document is a voluntary announcement published on the Hong Kong Exchange regarding clinical trial results for a pharmaceutical product. It contains no financial statements, no shareholder voting, no SEC form references, no governance changes, and no capital transactions. It is not itself a detailed report (like an annual report or interim report), nor is it a certification or proxy solicitation. It is a standalone corporate announcement of non-financial, operational news, fitting the ‘Regulatory Filings’ catch-all category for miscellaneous regulatory announcements.
2026-06-10 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Transaction in Own Shares Classification · 92% confidence The document is a voluntary on‐market purchase announcement describing the Company’s purchase of its own shares under its 2026 Share Award Scheme, including number of shares, price and trustee details. This is a report of a transaction in the company’s own shares (share buyback) rather than a financial report or earnings release. Therefore it falls under the “Transaction in Own Shares” category.
2026-06-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.